RiboPro B.V.

RIBOPRO is a leading Contract Development and Manufacturing Organisation (CDMO) specialising in high-quality messenger RNA (mRNA) technologies for the pharmaceutical and biotechnology industries.

Established in early 2020 by a team of scientists each with over a decade of experience in mRNA and delivery systems, RIBOPRO is headquartered in Oss, Noord-Brabant, Netherlands. The company is dedicated to accelerating the development of mRNA therapeutics and vaccines, providing comprehensive support from initial research through to clinical trials and commercialisation. RIBOPRO's commitment to innovation and quality has positioned it as a trusted partner for life-science pioneers worldwide.

Key Products and Services:

• Custom mRNA Synthesis: Design and synthesis of tailored mRNA sequences to meet specific research and therapeutic needs.

• Off-the-Shelf mRNA Products: A range of readily available mRNA products, including eGFP mRNA and PLuc mRNA, suitable for various research applications.

• Lipid Nanoparticle (LNP) Formulation: Development of advanced LNP formulations to enhance mRNA delivery and efficacy.

• GMP-Grade Manufacturing Services: Production of mRNA under Good Manufacturing Practice (GMP) conditions, ensuring compliance with regulatory standards for clinical applications.

• Analytical and Process Development: Comprehensive analytical services and process development to optimise mRNA production and quality.

RIBOPRO collaborates with esteemed partners such as Ardena, Medace, and Mercurna to provide end-to-end solutions for mRNA therapy development. These partnerships enhance RIBOPRO's capabilities in GMP development, regulatory approval, and innovative therapeutic applications. With a strong focus on research and development, RIBOPRO continues to advance mRNA and delivery technologies, ensuring best-in-class quality and safety for its clients.

In its commitment to supporting global health initiatives, RIBOPRO has also engaged with the Wellcome Leap Health Breakthrough Network to provide access to cGMP-formulated RNA for emergency situations. This collaboration underscores RIBOPRO's dedication to addressing urgent healthcare challenges through rapid and reliable mRNA solutions.

For more information, please visit ribopro.eu.